

# Kirk E Evoy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7618772/publications.pdf>

Version: 2024-02-01

37  
papers

943  
citations

567144

15  
h-index

454834

30  
g-index

37  
all docs

37  
docs citations

37  
times ranked

1023  
citing authors

#	ARTICLE	IF	CITATIONS
1	Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. <i>Drug and Alcohol Dependence</i> , 2022, 237, 109518.	1.6	19
2	Stop the Bleed: An Interprofessional Community Service Learning Project Assessing the Efficacy of Pharmacist-Led Hemorrhage Control Education for Laypersons. <i>Disaster Medicine and Public Health Preparedness</i> , 2021, 15, 271-276.	0.7	5
3	Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. <i>Addiction</i> , 2021, 116, 1505-1511.	1.7	42
4	Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update. <i>Drugs</i> , 2021, 81, 125-156.	4.9	94
5	Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 1055-1064.	1.0	17
6	Prevalence of and Factors Associated with Gabapentinoid Use and Misuse Among Texas Medicaid Recipients. <i>Clinical Drug Investigation</i> , 2021, 41, 245-253.	1.1	5
7	Letter to the Editor: Comment on "Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth" Pain and Therapy, 2021, 10, 751-755.	1.5	1
8	Considering the Potential Benefits of Over-the-Counter Naloxone. <i>Integrated Pharmacy Research &amp; Practice</i> , 2021, Volume 10, 13-21.	0.9	20
9	Authors' Reply to Bonnet et al. "Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update" <i>Drugs</i> , 2021, 81, 615-617.	4.9	3
10	Pharmacist counseling when dispensing naloxone by standing order: A secret shopper study of 4 chain pharmacies. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, 61, e94-e99.	0.7	17
11	Reply to Letter to the Editor Regarding Article: "Considering the Potential Benefits of Over-The-Counter Naloxone" [Response To Letter]. <i>Integrated Pharmacy Research &amp; Practice</i> , 2021, Volume 10, 77-78.	0.9	0
12	Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids. <i>Mental Health Clinician</i> , 2021, 11, 225-230.	0.5	5
13	Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S89-S99.	1.0	15
14	Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 81-86.	0.7	30
15	Prevalence and characteristics of self-reported kratom use in a representative US general population sample. <i>Journal of Addictive Diseases</i> , 2020, 38, 506-513.	0.8	33
16	National outpatient medication utilization for opioid and alcohol use disorders from 2014 to 2016. <i>Journal of Substance Abuse Treatment</i> , 2020, 119, 108141.	1.5	3
17	Receipt of Substance Use Counseling Among Ambulatory Patients Prescribed Opioids in the United States. <i>Substance Abuse: Research and Treatment</i> , 2020, 14, 117822181989458.	0.5	1
18	Reply. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, e22-e23.	0.7	0

#	ARTICLE	IF	CITATIONS
19	Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS). <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 953-958.	1.5	70
20	Comparative-effectiveness of ceftaroline and daptomycin as first-line MRSA therapy for patients with sepsis admitted to hospitals in the United States Veterans Health Care System. <i>Hospital Practice (1995)</i> , 2019, 47, 186-191.	0.5	3
21	State-Level Approaches to Expanding Pharmacists's™ Authority to Dispense Naloxone May Affect Accessibility. <i>JAMA Internal Medicine</i> , 2019, 179, 1442.	2.6	7
22	Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics. <i>Substance Abuse: Research and Treatment</i> , 2019, 13, 117822181984420.	0.5	19
23	Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2019, 59, 779-782.	0.7	18
24	A pilot study assessing the addition of a Quit and Win program to pharmacist-led intensive smoking cessation therapy in a predominantly underserved, minority population. <i>Tobacco Prevention and Cessation</i> , 2019, 5, 44.	0.2	1
25	Predictors of Gabapentin Overuse With or Without Concomitant Opioids in a Commercially Insured U.S. Population. <i>Pharmacotherapy</i> , 2018, 38, 436-443.	1.2	37
26	Naloxone Accessibility Without a Prescriber Encounter Under Standing Orders at Community Pharmacy Chains in Texas. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1934.	3.8	53
27	Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?. <i>Substance Abuse: Research and Treatment</i> , 2018, 12, 117822181880131.	0.5	42
28	Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis. <i>Side Effects of Drugs Annual</i> , 2018, 40, 447-461.	0.6	0
29	Pimavanserin: A Novel Drug Approved to Treat Parkinson's Disease Psychosis. <i>Innovations in Clinical Neuroscience</i> , 2018, 15, 16-22.	0.1	17
30	Abuse and Misuse of Pregabalin and Gabapentin. <i>Drugs</i> , 2017, 77, 403-426.	4.9	295
31	Early Use of Ceftaroline Fosamil in the United States Veterans Health Care System. <i>Drugs</i> , 2017, 77, 1345-1351.	4.9	10
32	Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis. <i>Side Effects of Drugs Annual</i> , 2017, , 359-372.	0.6	1
33	Volunteering as medical staff at a diabetes summer camp as a component of a pharmacy residency program. <i>Currents in Pharmacy Teaching and Learning</i> , 2016, 8, 437-441.	0.4	3
34	Combination bupropion SR and varenicline for smoking cessation: a systematic review. <i>American Journal of Drug and Alcohol Abuse</i> , 2016, 42, 129-139.	1.1	33
35	Aflibercept: Newly Approved for the Treatment of Macular Edema Following Central Retinal Vein Occlusion. <i>Annals of Pharmacotherapy</i> , 2013, 47, 819-827.	0.9	14
36	Ranibizumab: The First Vascular Endothelial Growth Factor Inhibitor Approved for the Treatment of Diabetic Macular Edema. <i>Annals of Pharmacotherapy</i> , 2013, 47, 811-818.	0.9	9

#	ARTICLE	IF	CITATIONS
37	Retrospective Cohort Evaluating the Comparative Effectiveness of Ceftaroline and Daptomycin as First-Line Therapies for Inpatient Treatment of Diabetic Foot Infection in the United States Veterans Health Care System. <i>Drugs - Real World Outcomes</i> , 0, , .	0.7	1